A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Inclusion Criteria:- Able to comprehend and sign an IRB approved Informed consent

   - Willingness and ability to comply with the FDA-mandated S.T.E.P.S.® program.

   - Male or female 18 years or older

   - Willing to use contraception

   - Pathologic diagnosis of renal cell carcinoma

   - Bi-dimensionally measurable disease

   - Evidence of disease progression prior to start of treatment

   - Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy

   - Adequate hematologic data: ANC.1.5; platelets>100x10^9

   - Adequate renal function: Creatinine clearance .50cc

   - Adequate liver function: Alkaline phos <3XULN AST/ALT <3XULN T.Bili <1.5XULN

   - ECOG performance status 0-1 Exclusion Criteria:- Known brain metastases.

   - Peripheral neuropathy.

   - Pregnant and/ or lactating female.

   - Unable to take a baby aspirin.